Maciej Gryziak1, Krzysztof Woźniak2, Leszek Kraj3, Rafał Stec2. 1. Department of Oncology, Medical University of Warsaw, Warsaw, Poland. Electronic address: maciej.gryziak@uckwum.pl. 2. Department of Oncology, Medical University of Warsaw, Warsaw, Poland. 3. Department of Oncology, Medical University of Warsaw, Warsaw, Poland; Department of Molecular Biology, Institute of Genetics and Animal Biotechnology Polish Academy of Sciences, Jastrzebiec, Poland.
Abstract
According to data provided by WHO (World Health Organization), hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths worldwide. Since the approval of sorafenib in 2008, several trials have assessed other particles for the treatment of HCC, but few have proven to be effective. ESMO (European Society for Medical Oncology) guidelines have been changed several times recently. This systematic review aims to describe both successful and failed trials of systemic treatments for HCC. Methods: We examined randomized, phase III trials of first- and second-line treatments in adults, identifying 23 fully-published trials and 2 reported as abstracts. The latest advances in immunotherapy were also briefly discussed. Conclusions: The landscape of HCC treatment has changed significantly in recent years. Several small molecule inhibitors currently form the core of HCC treatment; however, immunotherapy is now emerging as a promising treatment option.
According to data provided by WHO (World Health Organization), hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths worldwide. Since the approval of sorafenib in 2008, several trials have assessed other particles for the treatment of HCC, but few have proven to be effective. ESMO (European Society for Medical Oncology) guidelines have been changed several times recently. This systematic review aims to describe both successful and failed trials of systemic treatments for HCC. Methods: We examined randomized, phase III trials of first- and second-line treatments in adults, identifying 23 fully-published trials and 2 reported as abstracts. The latest advances in immunotherapy were also briefly discussed. Conclusions: The landscape of HCC treatment has changed significantly in recent years. Several small molecule inhibitors currently form the core of HCC treatment; however, immunotherapy is now emerging as a promising treatment option.
Authors: Ji Ah Kim; Sun Jae Park; Seulggie Choi; Jooyoung Chang; Seogsong Jeong; Joseph C Ahn; Gyeongsil Lee; Joung Sik Son; Sang Min Park Journal: Sci Rep Date: 2022-06-14 Impact factor: 4.996
Authors: Brian De; Sweet Ping Ng; Amy Y Liu; Santiago Avila; Randa Tao; Emma B Holliday; Zachary Brownlee; Ahmed Kaseb; Sunyoung Lee; Kanwal Raghav; Jean-Nicolas Vauthey; Bruce D Minsky; Joseph M Herman; Prajnan Das; Grace L Smith; Cullen M Taniguchi; Sunil Krishnan; Christopher H Crane; Clemens Grassberger; Theodore S Hong; Steven H Lin; Albert C Koong; Radhe Mohan; Eugene J Koay Journal: J Hepatocell Carcinoma Date: 2021-03-03
Authors: Monica A Kamal; Yasmine M Mandour; Mostafa K Abd El-Aziz; Ulrike Stein; Hend M El Tayebi Journal: Molecules Date: 2022-08-28 Impact factor: 4.927